IRVINE, Calif., Nov. 10, 2023 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the “Company”) a global provider of advanced medical products today announced that it will participate in the 14th Annual Craig-Hallum Alpha Select Conference on November 16, 2023, at the Sheraton New York Times Square Hotel in New York City. Zackary Irani, Chief Executive Officer of Biomerica will be hosting meetings during the event, which consists of one-on-one and small group meetings.
About Biomerica (NASDAQ: BMRA)
Biomerica, Inc. (www.biomerica.com) is a global biomedical technology company that develops, patents, manufactures and markets advanced diagnostic and therapeutic products used at the point-of-care (in home and in physicians' offices) and in hospital/clinical laboratories for detection and/or treatment of medical conditions and diseases. The Company's products are designed to enhance the health and well-being of people, while reducing total healthcare costs. Biomerica is primarily focused on gastrointestinal and inflammatory diseases where the Company has multiple diagnostic and therapeutic products in development.
Corporate Contact:
Zack Irani
949-645-2111
investors@biomerica.com
| Last Trade: | US$3.58 |
| Daily Change: | 0.12 3.47 |
| Daily Volume: | 10,184 |
| Market Cap: | US$65.660M |
April 23, 2025 February 26, 2025 February 19, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
